Maintenance Tx With Guselkumab for UC Meets All Endpoints :

The monoclonal antibody in development as maintenance therapy for people with moderately to severely active ulcerative colitis was more effective than placebo.

Related Keywords

Chicago , Illinois , United States , Massachusetts , Boston , Washington , David Rubin , Guselkumab Tremfya , Ashwin Ananthakrishnan , Janssen Johnson , Drug Administration , Colitis Center At Massachusetts , Digestive Disease Week , Medscape Medical , Inflammatory Bowel Disease Questionnaire , Colitis Center , Massachusetts General Hospital ,